MM&M/Publicis Health's first Diversity Survey reveals some notable shifts to making the healthcare industry more inclusive, yet many agencies didn't feel like opening up about their diversity numbers.
Those on the vanguard of transformation include a number of upstarts and veteran gurus taking on historic challenges plaguing health data.
Industry opponents say the end is nigh for pharma's ability to deduct expenses for consumer drug advertising, but those who've found their calling in healthcare comms ought to have something to say about that.
Purdue's decision to pull OxyContin sales reps highlights what has been the biggest part of marketing budgets. Did we just see the tipping point?
It was at an MM&M event back in late 2013 that I got my first glimpse of how this industry feels about big data.
The combined company wields greater power to disrupt brand profits.
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
Management turnover has brought the opportunity to keep up the pressure.
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Our goal is to make gender parity a priority, and to keep our spotlight trained on it.